Adverse outcome associated with daratumumab-based treatments in relapsed/refractory multiple myeloma patients with amplification of chromosome arm 1q21: a single-center retrospective experience
Emiliano Barbieri, Monica Maccaferri, Giovanna Leonardi, Francesca Giacobbi, Giorgia Corradini, Ivana Lagreca, Patrizia Barozzi, Leonardo Potenza, Roberto Marasca, Mario Luppi
Topics & Concepts
DaratumumabMedicineHematologySingle CenterInternal medicineRetrospective cohort studyMultiple myelomaOncologyRefractory (planetary science)LenalidomideBiologyAstrobiologyMultiple Myeloma Research and TreatmentsPeptidase Inhibition and AnalysisProtein Degradation and Inhibitors